Latest results from MDA immunotherapy trial for mCRPC using ipilimumab. Another clinical study helping to define PCa patient profiles for immunotherapy treatment.
From the MedPageToday article:
A small clinical study of checkpoint inhibitors for metastatic castration-resistant prostate cancer (mCRPC) identified favorable and unfavorable subgroups that might help inform use of the drugs in a disease that generally has proven unresponsive to immunotherapy..
Six of nine patients whose tumors had favorable characteristics -- defined by pretreatment levels of two immune-cell parameters and/or robust antigen-specific T-cell responses -- remained alive 33 to 54 months after treatment with ipilimumab (Yervoy). All nine of the patients had either radiographic or clinical progression-free survival (rcPFS) exceeding 6 months and overall survival (OS) greater than 12 months. Two of the patients had low tumor mutational burden (TMB), which is often associated with lack of response to immune therapy.
. . .
The findings from this study and others have guided additional research in several directions, including combination immune checkpoint inhibition in mCRPC.
"We published a study several years ago showing that when you give anti-CTLA-4, interferon-gamma is produced by the T cells and then PD-1 and PD-L1 are upregulated," said senior author Padmanee Sharma, MD, PhD, also of MD Anderson. "That suggests that coming in with a combination might be better, and we actually have a larger ongoing study evaluating anti-CTLA-4 and anti-PD-1. We're also looking at predictive biomarkers."
A next step would be a prospective study to evaluate immune checkpoint inhibition in patients who have biomarker-positive results, she added. Research to date has shown that tumor mutation types vary from patient to patient, providing a rationale for evaluating neoantigen vaccines with immune checkpoint inhibitors.
MedPageToday article is here:
Defining a Role for Immunotherapy in mCRPC
— Ipilimumab active in subgroup with favorable pretreatment tumor characteristics, robust T-cell response - April 3, 2020
medpagetoday.com/hematology...
And the Science Translational Medicine article is here:
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer - 01 April 2020
stm.sciencemag.org/content/...
As FPC Science guru is know to say, "The Science Is Coming".
Stay Safe & Be Well - Captain K9
